Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
November 06, 2019 16:02 ET
|
Ascendis Pharma A/S
– A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor – ...
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
September 12, 2019 16:20 ET
|
Ascendis Pharma A/S
– TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of...
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
March 25, 2019 14:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 25, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
March 04, 2019 06:30 ET
|
Ascendis Pharma A/S
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
January 07, 2019 09:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
September 17, 2018 16:10 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting
July 23, 2018 16:44 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference Call on November 16
November 02, 2017 18:45 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...